Siemens Healthineers Completes PET Detector Manufacturing Expansion Project in Tennessee, USA
Siemens Healthineers recently completed the expansion and renovation project of its PET detector center in Rockford, Tennessee, USA, with a total investment of $43.6 million. The project aims to enhance PET detector manufacturing capacity to meet the growing demand for PET/CT scanning equipment. The project added 40,000 square feet of building area to the existing 97,000-square-foot campus and renovated 7,500 square feet of existing space. The Rockford facility is Siemens Healthineers' only manufacturing site globally for producing PET detectors used in its PET/CT systems. The expansion includes 36,000 square feet of dedicated manufacturing space and a 4,000-square-foot expansion of R&D facilities; meanwhile, the company also renovated...
2026-09-10
American Society of Nuclear Cardiology Releases New 2026 Guidelines for Stress Testing in SPECT and PET Myocardial Perfusion Imaging
The American Society of Nuclear Cardiology (ASNC) has recently developed and released the "2026 ASNC Guidelines for Stress Testing in SPECT and PET Myocardial Perfusion Imaging." The guidelines have been published online in the Journal of Nuclear Cardiology and will replace the 2016 version to reflect changes in the field of nuclear cardiology over the past decade in terms of technology application, examination workflows, and clinical assessment. The new guidelines focus on stress testing in single-photon emission computed tomography (SPECT) and positron emission tomography (PET) myocardial perfusion imaging, updating recommendations on patient preparation, selection of stress testing modalities, safety management, protocols for different imaging modalities, image interpretation, and report writing. The guideline chair and lead...
2026-09-10
South Korea's First Animal Radiopharmaceutical Approved for the Treatment of Feline Hyperthyroidism
The Korea Atomic Energy Research Institute announced on September 10 that Thyrokitty Injection (I-131), a radiopharmaceutical for the treatment of feline hyperthyroidism developed by the research team led by Dr. Lim Jae-cheong, has obtained an animal drug manufacturing license issued by the Animal and Plant Quarantine Agency of South Korea. This is South Korea's first animal radiopharmaceutical to receive final product approval, marking the transition of related technologies that had previously been mainly at the R&D stage into clinical therapeutic application for pets. Feline hyperthyroidism is a relatively common endocrine disease in older cats, mainly characterized by excessive secretion of thyroid hormones. According to reports, approximately 10% of cats aged 10 and above may suffer from this disease. Traditional treatment methods typically require...
2026-09-10
Domestically Developed "Boron Neutron Capture Therapy System" Enters the National Special Review Procedure for Innovative Medical Devices
Recently, the Medical Device Technical Review Center of the National Medical Products Administration issued a public notice on the review results of applications for the Special Review Procedure for Innovative Medical Devices (No. 14 of 2026). The boron neutron capture therapy system independently developed by Huapeng Neutron Technology (Hangzhou) Co., Ltd. has officially entered the National Special Review Procedure for Innovative Medical Devices after the public notice period. Screenshot from the official website of the Medical Device Technical Review Center of the National Medical Products Administration. The Special Review Procedure for Innovative Medical Devices is a review channel established by the National Medical Products Administration to encourage medical device innovation and promote the application of new technologies, effective since December 1, 2018. According to the relevant procedures, drug regulatory authorities and technical institutions will, on the premise of not lowering standards and not reducing procedures,...
2026-09-10
ITM and SpiroChem Announce Strategic Collaboration to Advance Novel Radiopharmaceutical Development
Garching/Munich, Germany and Basel, Switzerland, September 8, 2026 – Radiopharmaceutical biotechnology company ITM Isotope Technologies Munich SE and Swiss collaborative research organization SpiroChem AG today announced a strategic drug discovery partnership focused on a novel radiopharmaceutical candidate within ITM's pipeline. The specific target and financial terms of the collaboration were not disclosed. Under the agreement, the parties will combine their respective capabilities to advance candidate discovery and optimization. SpiroChem will leverage its drug discovery platform, macrocycle library, and screening engine to lead hit identification and optimization, while ITM will provide...
2026-09-09
Penza State University in Russia Develops Training Simulator for X-ray Image Defect Recognition
Researchers at Penza State University in Russia have developed an interactive training simulator for identifying defects in X-ray images, aimed at helping medical students and residents more accurately assess abnormalities in medical images and understand the physical causes behind different image defects. X-ray image quality directly affects the efficiency of pathological change detection and clinical diagnostic judgment. Factors such as equipment condition, exposure parameters, radiation dose, and quantum noise levels can all lead to degraded image quality. Therefore, radiologic technologists and radiologists need not only to identify lesions in images, but also to assess image quality and determine whether defects such as low contrast, noise, blur, and artifacts may affect diagnosis...
2026-09-09
GE HealthCare's StarGuide GX Digital 4D CZT SPECT/CT Receives FDA 510(k) Clearance in the U.S.
GE HealthCare recently announced that its new digital 4D CZT SPECT/CT system, StarGuide GX, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The system had previously obtained CE marking, and this U.S. clearance marks progress in the clinical adoption of its next-generation molecular imaging technology. Designed for theragnostics and precision medicine needs, StarGuide GX is a comprehensive SPECT/CT system. It supports imaging at multiple energy levels, enables general-purpose SPECT imaging, and is tailored for emerging tracer applications, including investigational α-emitters, aiming to provide imaging support for clinicians and researchers exploring new pathways in diagnosis, treatment planning, and therapeutic response monitoring.
2026-09-09
Australia's First ZAP-X Gyroscopic Radiosurgery Platform to Be Installed at St Vincent's Hospital Sydney
ZAP Surgical Systems has announced that GenesisCare will become the first cancer treatment provider in Australia to introduce the ZAP-X Gyroscopic Radiosurgery® platform. The device is expected to be installed this month at GenesisCare's center at St Vincent's Hospital in Sydney, New South Wales, with the first patients anticipated to begin treatment before the end of the year. The deployment of the ZAP-X platform will enhance GenesisCare's neuro-oncology treatment capabilities in Sydney, enabling it to deliver dedicated stereotactic radiosurgery (SRS). Previously, SRS patients were primarily treated using cobalt-60 systems and multi-purpose radiotherapy linear accelerators. The ZAP-X, in contrast, is a dedicated platform designed for non-inv...
2026-09-09
Alpha-9 Oncology Initiates Phase 1 Clinical Trial of GRPR-Targeted Radiotherapy, First Patient Dosed
Alpha-9 Oncology, a U.S. clinical-stage radiopharmaceutical company, recently announced that the first patient has been dosed in its Phase 1 clinical trial evaluating two GRPR-targeted radiopharmaceuticals. The study involves the actinium-225-labeled compound 225Ac-A9-0642 and the lutetium-177-labeled compound 177Lu-A9-0631, primarily enrolling patients with breast cancer and other solid tumors, with data expected to be released by the end of 2027. According to the company, both 225Ac-A9-0642 and 177Lu-A9-0631 target the gastrin-releasing peptide receptor (GRPR). GRPR is considered a solid tumor-associated target with potential clinical value in breast cancer and other solid tumors. 225Ac-A9-0642 is Alpha-9's first actinium-225 GRPR-targeted compound to enter clinical evaluation...
2026-09-09
South Korea's DuChemBio to Build Country's First Radiopharmaceutical CDMO Plant
South Korean radiopharmaceutical therapy company DuChemBio will build the country's first contract development and manufacturing organization (CDMO) plant dedicated to radiopharmaceuticals, in response to growing demand for radiopharmaceuticals used in the diagnosis and treatment of cancer and neurological diseases. DuChemBio is a subsidiary of healthcare distributor Geo-Young Group. The company recently signed an investment agreement with North Jeolla Province and the city of Jeongeup to invest KRW 34.3 billion (approximately USD 25.5 million) in building a new plant in Jeongeup. The company stated that this is the largest investment since Geo-Young acquired DuChemBio. According to the plan, the new facility will integrate radioisotope production...
2026-09-08
Argentina Plans to Commission RA-10 Multipurpose Reactor in 2027
Argentina's National Atomic Energy Commission (CNEA) and the Nuclear Affairs Secretariat recently stated that the RA-10 multipurpose research reactor at the Ezeiza Atomic Centre is planned to begin commissioning before the end of this year, with the goal of achieving operation in 2027. (Image source: CNEA) According to the project site, RA-10 is currently in its final phase, with approximately 530 workers completing the remaining construction and system testing in preparation for subsequent reactor commissioning and operation. The project is currently about 96% complete overall. RA-10 is a 30 MW open-pool multipurpose research reactor that will provide products and services to the medical, scientific, technological, and industrial sectors once completed. Among these, molybdenum-99 will be one of its key products...
2026-09-08
Cancer Hospital of the First Hospital of Jilin University Established, Granted Configuration Permit for Heavy Ion Radiotherapy System
Recently, the 7th Bethune Conference on New Advances in Cancer Treatment was held in Changchun, Jilin Province. The conference coincided with the 80th anniversary of Jilin University and the 20th anniversary of the Cancer Center of the First Hospital of Jilin University, aiming to establish a high-level academic exchange platform and promote the continuous improvement of cancer diagnosis and treatment capabilities in the three northeastern provinces. During the conference, the inauguration ceremony of the Cancer Hospital of the First Hospital of Jilin University was also held. According to reports, the newly established Cancer Hospital will, based on the coordinated development of the original Cancer Center, integrate three advantageous disciplines—oncology, hematology, and radiation oncology—further improve the multidisciplinary collaborative diagnosis and treatment model, promote smoother connections in cancer diagnosis and treatment processes, and enhance comprehensive treatment capabilities for difficult cancers. The conference also...
2026-09-08
Japanese Research Uses Tau PET to Reveal Association with Symptom Progression in Progressive Supranuclear Palsy
A research team at the National Institutes for Quantum Science and Technology (QST) in Japan recently announced findings from a study on progressive supranuclear palsy (PSP). Using their self-developed tau PET imaging technology, the researchers conducted follow-up scans on the same group of PSP patients at approximately one-year intervals, confirming for the first time in living brains that the faster tau protein accumulates in the globus pallidus region deep within the brain, the faster patient symptoms progress. The findings were published on September 5, 2026, in the international neurology journal *Movement Disorders*. Characteristic tau protein accumulation regions in PSP Progressive supranuclear palsy is a progressive neurodegenerative disease occurring in middle-aged and older adults, with common manifestations including increased risk of falls, difficulty with movement, eye movement disorders, postural instability, and cognitive dysfunction. There is currently no therapy that can cure or halt disease progression; therefore, establishing biomarkers that can objectively reflect disease changes and treatment efficacy has been a critical issue in drug development. Previous autopsy studies have shown that abnormal tau protein accumulation in the brains of PSP patients is an important pathological feature, particularly concentrated in deep brain regions such as the globus pallidus and midbrain. However, autopsy samples cannot be used for long-term dynamic observation, and how tau protein accumulation changes over time and how it corresponds to symptom progression had previously remained unclear. In recent years, positron emission tomography (PET) has made it possible to observe tau protein in living brains, but existing studies have mainly shown that tau protein increases over time without sufficiently demonstrating a direct association between these changes and symptom worsening. In this study, the research team used the PET radiopharmaceutical 18F-PM-PBB3 developed by QST, namely florzolotau (18F), to perform two PET examinations on 26 PSP patients and 10 healthy controls, conducted at baseline and approximately one year later. The researchers combined 57 brain regions identified by MRI and performed multivariate analysis of PET signal changes to identify PSP-related tau protein accumulation regions and their spread over time. The results showed that at baseline, tau protein in PSP patients was primarily accumulated in subcortical regions such as the globus pallidus and midbrain, consistent with previous reports. Follow-up imaging at one year showed further increases in tau protein accumulation in the globus pallidus, along with marked increases in tau accumulation in the frontoparietal lobes and cerebellar white matter, suggesting that during the course of PSP, tau protein may spread from deep brain regions to the cerebral cortex and cerebellar-related areas. The research team further focused on Richardson's syndrome, the most typical and common subtype of PSP. This subtype typically progresses rapidly, and the 18 patients with this subtype included in this study showed significant increases in PSP rating scale scores within one year. The analysis found that changes in tau protein accumulation in the globus pallidus showed the strongest correlation with the degree of symptom progression; that is, the faster tau protein accumulated in this region, the more pronounced the worsening of patient symptoms. Analyses of individual patients likewise showed that globus pallidus tau protein accumulation can reflect the course of PSP from mild to severe stages. The researchers believe that serial tau PET imaging has the potential to serve as a novel imaging biomarker for assessing PSP disease progression, and also provides a basis for tau-targeted therapeutic strategies: if future therapies can inhibit tau protein accumulation, it may be possible to slow symptom progression. Next steps still require longer-term follow-up in a larger number of patients to validate the relationship between changes in tau protein accumulation and overall symptom progression and treatment response. The imaging assessment method established in this study may not only be used for disease monitoring and clinical trial efficacy evaluation in PSP, but may also be extended to research on other tau protein-related neurodegenerative diseases and dementias, providing new technical support for the diagnosis and therapeutic development of related diseases.
2026-09-07
China officially promotes Hualong One 2.0 Gen-III+ nuclear power technology to the global market
Nine key safety indicators of the Hualong One 2.0 Gen-III+ nuclear power technology have been significantly improved, the number of cabinets in the new-generation Harmony system has been reduced by approximately 40%, and the world's first 8.6-meter-aperture solar thermal collector, Yuanyao-1, can achieve a photoelectric efficiency of 17%... These were the highlights reported by this journalist at the CGN 2026 Sustainable Development Conference held in Shenzhen on September 7. At the conference, CGN officially released the "2025 CGN Sustainable Development Report," and simultaneously launched its global responsibility brand, the "CGN Firefly Plan." As the APEC Economic Leaders' Meeting draws near, Shenzhen is becoming the focus of Asia-Pacific attention. On September 7, CGN, headquartered in Shenzhen, hosted a sustainable development conference themed "Green Energy Illuminating Mountains and Seas, Joining Hands to Create the Future," showcasing China's clean energy development landscape and its latest progress in going global to think tanks, media, and other stakeholders from APEC member economies and countries jointly building the "Belt and Road."
2026-09-07
Atom High-Tech Signs Memorandum of Cooperation with Cambodia's Calmette Hospital and Others to Advance Nuclear Medicine Capacity Building
On September 4, Atom High-Tech, Cambodia's Calmette Hospital, and FFS Company held a trilateral memorandum of cooperation signing ceremony in Beijing. Huo Yingying, Deputy Secretary of the Party Committee of China Isotope & Radiation Corporation (CIRC), attended and delivered a speech, while Zhang Yiming, Secretary of the Party Committee and Chairman of Atom High-Tech, signed on behalf of the company. Established in 1950, Calmette Hospital is one of Cambodia's largest and most technologically advanced public hospitals and serves as a national referral center. It undertakes three core missions: delivering high-quality medical services, training health professionals, and conducting medical research. Currently, the hospital is actively advancing its nuclear medicine capacity by establishing the country's first nuclear medicine department, further improving its oncology diagnosis and treatment and molecular imaging service systems...
2026-09-07
Baiyunshan Xike Visits Jiujiang, Jiangxi to Explore Nuclear Medicine Industry Chain Cooperation
Recently, a delegation from Guangzhou Baiyunshan Xike Health Pharmaceutical Co., Ltd., a subsidiary of Guangzhou Pharmaceutical Holdings Limited (GP Corp.), visited Jiujiang City, Jiangxi Province, conducting field inspections and discussion exchanges in Ruichang City, Jiujiang Economic Development Zone, and Pengze County, focusing on cooperation across the full nuclear medicine industry chain. Liu Hong, Director of the Scientific Research Project Management Department of GP Corp. and Chairman and General Manager of Baiyunshan Xike, led the core team in exchanges with Chen Shuilian, Member of the Party Leadership Group and Vice Mayor of Jiujiang Municipal People's Government, as well as responsible officials from Ruichang City, Pengze County, and Jiujiang Economic Development Zone, reaching multiple consensuses on subsequent cooperation. The inspection covered key facilities including the Ruichang Institute of Nuclear Physics Applications, the Biomedical (Nuclear) Industrial Park in Jiujiang Economic Development Zone, and the Jiangxi Tianhong Nuclear Technology project site in Pengze County. The delegation conducted in-depth visits to research laboratories, industrial parks, and projects under construction to understand local capabilities in nuclear technology research, isotope R&D infrastructure, project construction progress, as well as land and industrial supporting conditions.
2026-09-07
Canada's AtomVie Opens Large-Scale Radiopharmaceutical R&D and Manufacturing Facility in Hamilton
On September 4, AtomVie Global Radiopharma, a radiopharmaceutical contract development and manufacturing organization, announced the official opening of its new state-of-the-art production facility at 10 Aeropark Boulevard, Hamilton, Ontario, Canada. The facility is designed to support the full-spectrum translation of radiopharmaceuticals from early-stage research and development, through clinical development, to commercial manufacturing. According to reports, the new facility represents an investment of over $160 million and spans 72,300 square feet, making it one of the largest single-site radiopharmaceutical R&D CDMO facilities in North America. The facility offers production capabilities ranging from low-throughput to high-throughput, increasing AtomVie's overall production capacity by more than tenfold, with dedicated spaces configurable to meet clients' subsequent R&D and commercialization needs.
2026-09-05
Radionuclide Ward Officially Launched at Xuguan Campus of Suzhou Nuclear Industry General Hospital under CNNC Medical
On September 3, the radionuclide ward of the Nuclear Medicine Department at the Xuguan Campus of Suzhou Nuclear Industry General Hospital, affiliated with CNNC Medical, was officially inaugurated and put into operation. The ward addresses the standardized radionuclide therapy needs of patients with tumors, thyroid diseases, and endocrine disorders, providing inpatient treatment services with isolation and protection conditions. According to reports, the newly launched radionuclide ward is equipped with radiation protection facilities and intelligent monitoring systems, enabling fully enclosed ward management, treatment process monitoring, and multi-level protection. Following the ward's commissioning, the Nuclear Medicine Department will expand from its previous examination-focused service model into a closed-loop service chain integrating radionuclide diagnosis, drug therapy, isolated hospitalization, and research follow-up, enhancing its capacity to manage complex and critically ill patients...
2026-09-05
Royal Victoria Hospital Belfast Introduces Photon-Counting CT, Becoming Ireland's First Hospital to Adopt the Technology
Royal Victoria Hospital Belfast recently introduced the Siemens Healthineers NAEOTOM Alpha.Prime photon-counting CT scanner, becoming the first hospital in Ireland to adopt this next-generation CT imaging technology. The hospital is part of the Belfast Health and Social Care Trust, and this installation is part of a long-term value partnership between the hospital and Siemens Healthineers. According to reports, the NAEOTOM Alpha.Prime photon-counting CT delivers ultra-high-resolution images and spectral data at lower radiation doses. Its 0.2 mm slice thickness helps clinicians visualize small blood vessels, fine anatomical structures, and early pathological changes, enabling more diagnostic information to be obtained in a single scan...
2026-09-03
China's largest single-building oncology nuclear medicine center to be completed and put into operation in Luzhou, Sichuan
On September 2, the "Myriad Weather in Sichuan · Starting Strong for the '15th Five-Year Plan'" Luzhou special press conference was held in Chengdu. The conference disclosed that China's largest single-building oncology nuclear medicine center is about to be completed and put into operation in Luzhou, Sichuan. Construction site of the Oncology Nuclear Medicine Center of the Affiliated Hospital of Southwest Medical University. The center is a key project of Sichuan Province's regional medical centers. The project has a total investment of 310 million yuan, covers an area of approximately 15,000 square meters, and plans more than 160 beds. It will integrate functions including nuclear medicine molecular imaging, nuclear drug R&D and preparation, radionuclide therapy, tumor radiotherapy, and specialized oncology diagnosis and treatment, and will be built into...
2026-09-03
IAEA 70th General Conference to Host Technical Cooperation Side Events Focusing on Radiotherapy Financing and African Nuclear Workforce Development
The 70th Regular Session of the International Atomic Energy Agency General Conference will be held from September 14 to 18, 2026, at the Vienna International Centre in Austria. During the session, delegates and technical experts from various countries will discuss the Agency's ongoing work and topics related to nuclear science and technology. The 70th Regular Session of the IAEA General Conference will take place from September 14 to 18, 2026, at the Vienna International Centre. (IAEA) As part of the arrangements related to the General Conference, the IAEA Department of Technical Cooperation will host two side events during the conference week, highlighting its technical cooperation support to Member States. One event will focus on financing for the expansion of radiotherapy services, while the other will...
2026-09-03
West Physics Acquires U.S. Medical Physics Services Provider RTS, Expanding Nuclear Medicine and Radiation Safety Service Network
West Physics Consulting, LLC, a U.S. provider of medical and health physics consulting services, announced on September 2, 2026, that it has acquired Radiographic Testing Services, Inc. (RTS). Headquartered in Albany, New York, RTS primarily provides medical physics services covering nuclear medicine, diagnostic radiology, radiation oncology, and Certified Radiological Equipment Safety Officer (CRESO)-related services. West Physics stated that this acquisition will integrate the strengths of both companies in customer service, quality management, and technical capabilities. Upon completion of the transaction, the company will add a new office in Albany, New York, and further expand its presence in Albany, New York...
2026-09-03
Reading Ranking
- 1 Chonnam National University Hospital in Hwasun, South Korea, Adopts Deepnoid's Chest X-ray AI Interpretation Solution "M4CXR"
- 2 South Korea's Medical Radiation Examinations Exceed 430 Million Annually, with CT Scans Accounting for 67.1% of Radiation Dose
- 3 CNNC-CNI assists in the launch of the high-quality nuclear medicine diagnosis and treatment project at Mianyang Central Hospital.
- 4 Russia Advances Radiopharmaceutical Development, Plans to Expand into Diagnostics and Treatment of Heart Disease and Other Conditions
- 5 Siemens Healthineers Completes PET Detector Manufacturing Expansion Project in Tennessee, USA
- 6 CGN Medical and West China Hospital of Sichuan University Sign Proton Therapy Innovation Technology Cooperation Agreement
- 7 China officially promotes Hualong One 2.0 Gen-III+ nuclear power technology to the global market
- 8 GE HealthCare's Photonova Spectra Photon-Counting CT Receives CE Mark, to Be Commercialized in Countries Recognizing CE Marking
- 9 Blueprint for Proton Therapy Center in Southeastern Busan, South Korea Unveiled to Address Regional Gap in Cancer Treatment Resources
- 10 Atom High-Tech Signs Memorandum of Cooperation with Cambodia's Calmette Hospital and Others to Advance Nuclear Medicine Capacity Building
- 11 Phase I of Jinjiang Ruisi Ke Particle Therapy Equipment Production Base Fully Operational
- 12 South Korea to Resume Actinium-225 Production Next Year to Ease Shortage of Raw Materials for Anti-Cancer Radiopharmaceuticals
- 13 CNNC Particle and Beijing Institute of Medical Device Testing Carry Out Joint Learning and Co-building Activity
- 14 Anambra State, Nigeria Strengthens Cooperation with Nuclear Regulatory Authority to Enhance Safety Management of Medical Radioactive Materials
- 15 Huzhou, Zhejiang Launches Phase I "Drug-Device Combination" Clinical Trial for the Province's First BNCT System